- Email: [email protected]
Albemarle reports 3Q 2013 results: catalysts
F O C U S business unit. The latter will consist of refinery Catalyst Solutions, Performance Catalyst Solutions, and Antioxidants. Each unit will have its own team of sales, R&D, process engineering, manufacturing and sourcing, and business strategy teams. Original Source: Chemical Weekly, 8 Oct 2013, 185 (Website: http://www.chemicalweekly.com) © Sevak Publications & Chemical Weekly Database P Ltd 2013
Albemarle reports 3Q 2013 results: catalysts Albermarle Corp’s generated net sales for catalysts segment in 3Q 2013 is $226.0 M, a 10% decrease from net sales in 3Q 2012. This was due to unfavourable pricing in refinery catalysts solutions on lower metals, pass through surcharges and unfavourable performance catalyst solutions volumes and pricing. Income for the segment was $57.5 M in 3Q 2013, down by 7% from 3Q 2012 results of $61.8 M. This was contributed by the higher manufacturing costs, lower pricing in performance catalysts solutions, and lower equity income from its unconsolidated jvs partly offset by higher refinery catalysts volumes and lower variable input costs. Original Source: Albemarle, 21 Oct 2013, (Website: http://www.albemarle.com/) © Albemarle Corporation 2013
Biolie: enzymes for aqueous phase oil extraction French company Biolie is expanding its catalogue and at the same time offering services based on its enzymebased extraction technology. It is aiming to go into production at start 2014. Biolie’s technology is a singlestep cracking process which extracts aqueous phase, solid phase, and emulsion oils from plants. It was developed using rape and sunflower seeds and has since been tested on a wide range of plant materials. The company offers its clients custom development services. It employs 4 people and its business model is based around 3 axies: R&D contracts, custom production contracts, and the sale of oils via its catalogue. It may also license out its technology for large scale markets such as agrofoodstuffs. Original Source: Chimie Pharma Hebdo, 28 Oct 2013, (652), (Website: http://www.industrie.com/chimie/) (in French) © ETAI Information 2013
JANUARY 2014
O N
C ATA LY S T S
Clariant and Lummus Novolen in catalyst development partnership The Catalysts Division of Swiss Clariant Group and CB&I’s Lummus Novolen Technology GmbH plan to combine and intensify their R&D efforts in order to develop improved polypropylene catalysts and Donor technologies. The new catalysts are developed in a new and advanced production facility for Ziegler-Natta catalysts. The companies signed a long-term partnership agreement in Aug 2013. Both Clariant and Lummus Novolen will invest around SFR 65 M in a production facility for PP catalysts at Clariant’s site in Louisville, KY, in the US. The plant is scheduled to come on-stream in 2015. Clariant predicts that the market for ZieglerNatta catalysts will grow above 5%/y during the next 5 years. Original Source: Chemie Plus – Chemische Rundschau, Sep 2013, (9), 11 (Website: http://www.chemische-rundschau.ch/) (in German) © AZ Medien 2013
Clariant introduces new low temperature bleaching catalysts Clariant introduces two bleach catalysts, namely, Peractive MnOx and Peractive MnTACN. These products are designed for low temperature automatic dishwashing (ADW) applications. The company has focused on using manganesebased bleach catalyst because manganese is less toxic than nickel, chromium, or cobalt salts. Peractive MnOx is non-mutagenic, non-toxic, non-sensitizing, non-irritant, and safe to use in consumer products. Original Source: HPC, Household and Personal Care Today, May-Jun 2013, 8 (3), 36,37,38,40 (Website: http://hpc-today.teknoscienze.com) © Teknoscienze Srl 2013
Clariant developing new catalysts in Brazil. Clariant has opened an R&D laboratory for catalysts for the oil and gas industry in Suzano, Brazil. The aim is to develop new generations of catalysts. Clariant expects Brazilian gas reserves to increase and domestic production to rise from the current 65 M cubic metre/day to 180 M cubic metre/day by 2020. Original Source: Chemie Plus – Chemische Rundschau, Aug 2013, (8), 4 (Website: http://www.chemieplus.ch) (in German) © AZ Medien 2013
Dow divests its global Polypropylene Licensing and Catalysts business to WR Grace The Dow Chemical Company announced that it has signed a definitive agreement under which Dow’s global Polypropylene Licensing and Catalysts business will be divested to WR Grace and Co for a sale price of $500 M. Dow expects to report a gain on this divestment and net proceeds will be directed toward the company’s main priorities of remunerating shareholders, debt reduction, and funding growth. The transaction is expected to close by end-2013, pending regulatory clearance. Original Source: Dow, 2013. Found on website SpecialChem Plastics and Elastomers Formulation, 17 Oct 2013, (Website: http://www.specialchem4polymers.com)
Dyadic International reports 3Q 2013 financial results Dyadic International Inc, a global leader in the commercial application of biotechnology for the discovery, development, and production of enzymes and other proteins, announced financial results for the quarter and nine months ended 30 Sep 2013. During the quarter, C1 licensees made significant progress. Dyadic achieved the technical milestone with BASF, specifically relating to the technology transfer. The completion of this milestone entitles Dyadic to the final milestone payment of $1,000,000 which will be recognized in 4Q 2013. Based on publicly available information, Dyadic expects Abengoa to begin production at its Hugoton, KS cellulosic ethanol plant in 1Q or 2Q 2014, with volume production occurring by mid-2014. Dyadic expects to receive royalty payments in conjunction with the operation of this facility in 2014. Original Source: Dyadic International, 14 Nov 2013, (Dyadic International, website: http://dyadic.com/) © Dyadic International 2013
US Court confirms the scope of Evonik’s patent rights in metathesis catalysts patent On 30 Oct 2013, Evonik Industries AG announced that the US Court for the District of Delaware issued its claim construction order and opinion in
3
Albemarle reports 3Q 2013 results: catalysts Albermarle Corp’s generated net sales for catalysts segment in 3Q 2013 is $226.0 M, a 10% decrease from net sales in 3Q 2012. This was due to unfavourable pricing in refinery catalysts solutions on lower metals, pass through surcharges and unfavourable performance catalyst solutions volumes and pricing. Income for the segment was $57.5 M in 3Q 2013, down by 7% from 3Q 2012 results of $61.8 M. This was contributed by the higher manufacturing costs, lower pricing in performance catalysts solutions, and lower equity income from its unconsolidated jvs partly offset by higher refinery catalysts volumes and lower variable input costs. Original Source: Albemarle, 21 Oct 2013, (Website: http://www.albemarle.com/) © Albemarle Corporation 2013
Biolie: enzymes for aqueous phase oil extraction French company Biolie is expanding its catalogue and at the same time offering services based on its enzymebased extraction technology. It is aiming to go into production at start 2014. Biolie’s technology is a singlestep cracking process which extracts aqueous phase, solid phase, and emulsion oils from plants. It was developed using rape and sunflower seeds and has since been tested on a wide range of plant materials. The company offers its clients custom development services. It employs 4 people and its business model is based around 3 axies: R&D contracts, custom production contracts, and the sale of oils via its catalogue. It may also license out its technology for large scale markets such as agrofoodstuffs. Original Source: Chimie Pharma Hebdo, 28 Oct 2013, (652), (Website: http://www.industrie.com/chimie/) (in French) © ETAI Information 2013
JANUARY 2014
O N
C ATA LY S T S
Clariant and Lummus Novolen in catalyst development partnership The Catalysts Division of Swiss Clariant Group and CB&I’s Lummus Novolen Technology GmbH plan to combine and intensify their R&D efforts in order to develop improved polypropylene catalysts and Donor technologies. The new catalysts are developed in a new and advanced production facility for Ziegler-Natta catalysts. The companies signed a long-term partnership agreement in Aug 2013. Both Clariant and Lummus Novolen will invest around SFR 65 M in a production facility for PP catalysts at Clariant’s site in Louisville, KY, in the US. The plant is scheduled to come on-stream in 2015. Clariant predicts that the market for ZieglerNatta catalysts will grow above 5%/y during the next 5 years. Original Source: Chemie Plus – Chemische Rundschau, Sep 2013, (9), 11 (Website: http://www.chemische-rundschau.ch/) (in German) © AZ Medien 2013
Clariant introduces new low temperature bleaching catalysts Clariant introduces two bleach catalysts, namely, Peractive MnOx and Peractive MnTACN. These products are designed for low temperature automatic dishwashing (ADW) applications. The company has focused on using manganesebased bleach catalyst because manganese is less toxic than nickel, chromium, or cobalt salts. Peractive MnOx is non-mutagenic, non-toxic, non-sensitizing, non-irritant, and safe to use in consumer products. Original Source: HPC, Household and Personal Care Today, May-Jun 2013, 8 (3), 36,37,38,40 (Website: http://hpc-today.teknoscienze.com) © Teknoscienze Srl 2013
Clariant developing new catalysts in Brazil. Clariant has opened an R&D laboratory for catalysts for the oil and gas industry in Suzano, Brazil. The aim is to develop new generations of catalysts. Clariant expects Brazilian gas reserves to increase and domestic production to rise from the current 65 M cubic metre/day to 180 M cubic metre/day by 2020. Original Source: Chemie Plus – Chemische Rundschau, Aug 2013, (8), 4 (Website: http://www.chemieplus.ch) (in German) © AZ Medien 2013
Dow divests its global Polypropylene Licensing and Catalysts business to WR Grace The Dow Chemical Company announced that it has signed a definitive agreement under which Dow’s global Polypropylene Licensing and Catalysts business will be divested to WR Grace and Co for a sale price of $500 M. Dow expects to report a gain on this divestment and net proceeds will be directed toward the company’s main priorities of remunerating shareholders, debt reduction, and funding growth. The transaction is expected to close by end-2013, pending regulatory clearance. Original Source: Dow, 2013. Found on website SpecialChem Plastics and Elastomers Formulation, 17 Oct 2013, (Website: http://www.specialchem4polymers.com)
Dyadic International reports 3Q 2013 financial results Dyadic International Inc, a global leader in the commercial application of biotechnology for the discovery, development, and production of enzymes and other proteins, announced financial results for the quarter and nine months ended 30 Sep 2013. During the quarter, C1 licensees made significant progress. Dyadic achieved the technical milestone with BASF, specifically relating to the technology transfer. The completion of this milestone entitles Dyadic to the final milestone payment of $1,000,000 which will be recognized in 4Q 2013. Based on publicly available information, Dyadic expects Abengoa to begin production at its Hugoton, KS cellulosic ethanol plant in 1Q or 2Q 2014, with volume production occurring by mid-2014. Dyadic expects to receive royalty payments in conjunction with the operation of this facility in 2014. Original Source: Dyadic International, 14 Nov 2013, (Dyadic International, website: http://dyadic.com/) © Dyadic International 2013
US Court confirms the scope of Evonik’s patent rights in metathesis catalysts patent On 30 Oct 2013, Evonik Industries AG announced that the US Court for the District of Delaware issued its claim construction order and opinion in
3